Search
CELL BANK Website

Back Back
Cell No. : Cell Name
RCB2226 : JHOC-9  update : 2022/07/05
CommentHuman cell line derived from ovarian clear cell carcinoma. Application consideration
Comment from the depositor
Terms and conditionsA prior written permission of the approver(Depositor) is necessary for any kind of use including academic use and for-profit use.
Remarks
approver's address
×
English
Address
Contact Us
cellbank.brc@riken.jp
RIKEN, BioResource Research Center
Cell Engineering Division
Dr.Cell Bank (ISHIKAWA Hiroshi)
Fax. +81-29-836-9130
Order Form Order Form(C-0005.pdf)   Approval Form(C-0006.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
Basic information Depositor Ishikawa, Hiroshi
Originator Ishikawa, H. & Yasuda, M.
Year of deposit 2005
Animal human < Mammals
Genus Homo
Species sapiens
Race Japanese
Gender Female
Age at sampling 34 years
Tissue ovary
Disease name clear cell carcinoma
Metastastatic ability Yes
Metastatsd tissue lymph node
Classification cancer
Year of origin 1998
Lifespan infinite
Morphology epithelial-like
Cellosaurus(Expasy) CVCL_4643
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Medium and additives DMEM/HamF12 + 20% FBS + 0.1mM NEAA
Antibiotics Free
Passage method (0.05% Trypsin + 0.02% EDTA) or (0.25% Trypsin + 0.04% EDTA)
Culture information Passage ratio 1 : 8 split
SC frequency Subculture : once/1-2 weeks, Medium Renewal : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
Isozyme LD, NP
STR(human) OK
Images
deposit info
lot info
Reference information Reference 0
User's Publication 19


To topTop
Reference

To topTop
User's Publication
20728  Mehner C, Hockla A, Coban M, Madden B, Estrada R, Radisky DC, Radisky ES.  Activity-based protein profiling reveals active serine proteases that drive malignancy of human ovarian clear cell carcinoma.  J Biol Chem  2022  102146  PubMed ID: 35716777   DOI: 10.1016/j.jbc.2022.102146
14932  Ota Y, Koizume S, Nakamura Y, Yoshihara M, Takahashi T, Sato S, Myoba S, Ohtake N, Kato H, Yokose T, Miyagi E, Miyagi Y.  Tissue factor pathway inhibitor‑2 is specifically expressed in ovarian clear cell carcinoma tissues in the nucleus, cytoplasm and extracellular matrix  Oncol Rep  2021  45(3):1023-1032  PubMed ID: 33650653   DOI: 10.3892/or.2021.7944
13249  Minagawa Y, Ishino K, Wada R, Kudo M, Naito Z, Takeshita T, Ohashi R.  High Expression of p21 as a Potential Therapeutic Target in Ovarian Clear-cell Carcinoma.  Anticancer Res  2020    PubMed ID: 32988887   DOI: 10.21873/anticanres.14576
13777  Kawata Y, Nagasaka K, Oda K, Makii C, Takeuchi M, Oki S, Honjo H, Kojima M, Miyagawa Y, Taguchi A, Tanikawa M, Sone K, Hiraike H, Matsumoto Y, Wada-Hiraike O, Ayabe T, Osuga Y, Fujii T.  Effect of murine double-minute 2 inhibitors in preclinical models of advanced clear cell carcinomas originating from ovaries and kidneys  Cancer Sci  2020  111(10):3824-3834  PubMed ID: 32713096   DOI: 10.1111/cas.14583
11839  Kuroda T, Ogiwara H, Sasaki M, Takahashi K, Yoshida H, Kiyokawa T, Sudo K, Tamura K, Kato T, Okamoto A, Kohno T.  Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma.  Gynecol. Oncol.  2019    PubMed ID: 31604667   DOI: 10.1016/j.ygyno.2019.10.002
9662  Jennifer X. Ji et al  Arginine depletion through ADI-PEG20 to treat argininosuccinate synthase deficient ovarian cancer, including small cell carcinoma of the ovary, hypercalcemic type  bioRxiv  2019  November 17    DOI: 10.1101/845586
14809  Yasuto Kinose, Dorothy Hallberg, Kai Doberstein, Gordon Mills, Tan Ince, Victor Velculescu, Fiona Simpkins, Ronny Drapkin  Abstract 1065: Comprehensive molecular and experimental characterization of ovarian clear cell carcinoma cell lines forin vivodrug development  Tumor Biology  2019      DOI: 10.1158/1538-7445.am2019-1065
9659  Elayne Chan-Penebre, Kelli Armstrong, Allison Drew, Alexandra R Grassian, Igor Feldman, Sarah K Knutson, Kristy Kuplast-Barr, Maria Roche, John Campbell, Peter Ho, Robert A Copeland, Richard Chesworth, Jesse J Smith, Heike Keilhack, Scott A Ribich  Selective Killing of SMARCA2- And SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models  Mol Cancer Ther   2017  16(5):850-860  PubMed ID: 28292935   DOI: 10.1158/1535-7163.MCT-16-0678
7404  Yanaihara N, Hirata Y, Yamaguchi N, Noguchi Y, Saito M, Nagata C, Takakura S, Yamada K, Okamoto A.  Antitumor effects of interleukin-6 (IL-6)/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary.  Mol. Carcinog.  2016  55:832-41  PubMed ID: 25856562   DOI: 10.1002/mc.22325
9636  Nozomu Yanaihara, Yukiko Noguchi 1, Misato Saito 1, Masataka Takenaka 1, Satoshi Takakura 2, Kyosuke Yamada 1, Aikou Okamoto 1  MicroRNA Gene Expression Signature Driven by miR-9 Overexpression in Ovarian Clear Cell Carcinoma  PLoS One  2016  11(9):e0162584  PubMed ID: 27612152   DOI: 10.1371/journal.pone.0162584
9661  Chinami Makii, Katsutoshi Oda, Yuji Ikeda, Kenbun Sone, Kosei Hasegawa, Yuriko Uehara, Akira Nishijima, Kayo Asada, Takahiro Koso, Tomohiko Fukuda, Kanako Inaba, Shinya Oki, Hidenori Machino, Machiko Kojima, Tomoko Kashiyama, Mayuyo Mori-Uchino, Takahide Arimoto, Osamu Wada-Hiraike, Kei Kawana, Tetsu Yano, Keiichi Fujiwara, Hiroyuki Aburatani, Yutaka Osuga, Tomoyuki Fujii  MDM2 Is a Potential Therapeutic Target and Prognostic Factor for Ovarian Clear Cell Carcinomas With Wild Type TP53  Oncotarget  2016  7(46):75328-75338  PubMed ID: 27659536   DOI: 10.18632/oncotarget.12175
7410  Takenaka M, Saito M, Iwakawa R, Yanaihara N, Saito M, Kato M, Ichikawa H, Shibata T, Yokota J, Okamoto A, Kohno T.  Profiling of actionable gene alterations in ovarian cancer by targeted deep sequencing.  Int. J. Oncol.  2015  46:2389-98  PubMed ID: 25846456   DOI: 10.3892/ijo.2015.2951
14315  Davis SJ, Sheppard KE, Anglesio MS, George J, Traficante N, Fereday S, Intermaggio MP, Menon U, Gentry-Maharaj A, Lubinski J, Gronwald J, Pearce CL, Pike MC, Wu A, Kommoss S, Pfisterer J, du Bois A, Hilpert F, Ramus SJ, Bowtell DD, Huntsman DG, Pearson RB, Simpson KJ, Campbell IG, Gorringe KL.  Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition  Mol Cancer Ther  2015  14(6):1495-503  PubMed ID: 25852062   DOI: 10.1158/1535-7163.MCT-15-0039
15031  Takaya A, Peng WX, Ishino K, Kudo M, Yamamoto T, Wada R, Takeshita T, Naito Z.  Cystatin B as a potential diagnostic biomarker in ovarian clear cell carcinoma  Int J Oncol  2015  46(4):1573-81  PubMed ID: 25633807   DOI: 10.3892/ijo.2015.2858
9658  Tomoko Kashiyama, Katsutoshi Oda, Yuji Ikeda, Yoshinobu Shiose, Yasuhide Hirota, Kanako Inaba, Chinami Makii, Reiko Kurikawa, Aki Miyasaka, Takahiro Koso, Tomohiko Fukuda, Michihiro Tanikawa, Keiko Shoji, Kenbun Sone, Takahide Arimoto, Osamu Wada-Hiraike, Kei Kawana, Shunsuke Nakagawa, Koichi Matsuda, Frank McCormick, Hiroyuki Aburatani, Tetsu Yano, Yutaka Osuga, Tomoyuki Fujii  Antitumor Activity and Induction of TP53-dependent Apoptosis Toward Ovarian Clear Cell Adenocarcinoma by the Dual PI3K/mTOR Inhibitor DS-7423  PLoS One  2014  9(2):e87220  PubMed ID: 24504419   DOI: 10.1371/journal.pone.0087220
17115  Hirata Y, Murai N, Yanaihara N, Saito M, Saito M, Urashima M, Murakami Y, Matsufuji S, Okamoto A.  MicroRNA-21 is a candidate driver gene for 17q23-25 amplification in ovarian clear cell carcinoma  BMC Cancer  2014  14:799  PubMed ID: 25366985   DOI: 10.1186/1471-2407-14-799
9635  Yoriko Yamashita, Shinya Akatsuka, Kanako Shinjo, Yasushi Yatabe, Hiroharu Kobayashi, Hiroshi Seko, Hiroaki Kajiyama, Fumitaka Kikkawa, Takashi Takahashi, Shinya Toyokuni  Met Is the Most Frequently Amplified Gene in Endometriosis-Associated Ovarian Clear Cell Adenocarcinoma and Correlates With Worsened Prognosis  PLoS One  2013  8(3):e57724  PubMed ID: 23469222   DOI: 10.1371/journal.pone.0057724
9657  Nozomu Yanaihara, Michael S Anglesio, Kazunori Ochiai, Yukihiro Hirata, Misato Saito, Chie Nagata, Yasushi Iida, Satoshi Takakura, Kyosuke Yamada, Tadao Tanaka, Aikou Okamoto  Cytokine Gene Expression Signature in Ovarian Clear Cell Carcinoma  Int J Oncol   2012  41(3):1094-100  PubMed ID: 22751940   DOI: 10.3892/ijo.2012.1533
17036  Wu S, Fukumoto T, Lin J, Nacarelli T, Wang Y, Ong D, Liu H, Fatkhutdinov N, Zundell JA, Karakashev S, Zhou W, Schwartz LE, Tang HY, Drapkin R, Liu Q, Huntsman DG, Kossenkov AV, Speicher DW, Schug ZT, Van Dang C, Zhang R.  Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma  Nat Cancer     2(2):189-200  PubMed ID: 34085048   DOI: 10.1038/s43018-020-00160-x



Back Back Return Top Page